We are very grateful to the supporters of the 32nd International Symposium on ALS/MND, held virtually on 7-10 December 2021:
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised.
Amylyx is a Cambridge-based pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders. Guided by our core values, we incorporate unconventional approaches through strong partnerships with industry leaders, scientists, doctors and organizations. We work collaboratively across everything we do to positively impact the lives of patients and their families.
Apellis Pharmaceuticals, Inc., is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in Complement, at the forefront of targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.
Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics, Inc. is a clinical-stage, biotechnology company focused on the development of best-in-class autologous cellular therapeutics for the treatment of highly debilitating neurodegenerative diseases.
Mitsubishi Tanabe Pharma America
Mitsubishi Tanabe Pharma America, Inc. (MTPA) is relentlessly focused on the goal of providing therapies for some of the most difficult-to-treat diseases, including amyotrophic lateral sclerosis (ALS). Our teams work diligently to develop smart options that will enable healthcare providers to offer safe and effective treatments for devastating illnesses. We thrive on solving complex problems in science and medicine and strive to make a real difference in the lives of people struggling with debilitating diseases.
QurAlis is trailblazing the path to conquering amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets with next-generation precision medicines. QurAlis’ proprietary platforms and unique biomarkers enable the design and development of drugs that act directly on disease-causing genetic alterations. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a deep pipeline of antisense oligonucleotides and small molecule programs including addressing sub-forms of ALS that account for the majority of ALS patients. For more information, please visit www.quralis.com or follow us on Twitter @QurAlisCo.